TIDMHYG TIDMSVCT 
 
 
   Seneca Growth Capital VCT Plc (the "Company") 
 
   16 September 2020 
 
   Realisations of Ordinary Share Investments and New Ordinary Share Net 
Asset Value ("NAV"). 
 
   Full Realisation of Ordinary Share Investment in Omega Diagnostics Group 
plc ("Omega") 
 
   Following the recent rise in Omega's share price on AIM, the Company has 
sold the remaining 400,000 Omega shares it retained, realising 
GBP296,166, an increase of GBP132,166 (unaudited) on their carrying 
value as at 30 June 2020, being the date of the most recently announced 
NAV per Ordinary Share. The Company has now sold a total of 2,293,868 
Omega shares from the Ordinary Share pool since 31 December 2019 fully 
realising the investment for a total of GBP987,318 and generating a 
profit versus original cost of GBP659,318 (a 3x return on the original 
investment). 
 
   Partial Realisation of Ordinary Share Investment in Scancell Holdings 
Plc ("Scancell") 
 
   The Directors are also pleased to report that the Company has sold 
1,049,730 Scancell shares from the Ordinary Share pool, realising 
GBP126,619 and generating a profit versus original cost of GBP63,110 (a 
2x return on the original investment) and an increase of GBP72,033 on 
their carrying value as at 30 June 2020. The Company's Ordinary Share 
pool retains 12,000,000 Scancell shares. 
 
   New Ordinary Share Net Asset Value 
 
   The Board have reviewed the carrying value of all Ordinary Share pool 
investments, including Scancell at a bid price of 15p per share as at 14 
September 2020, and report that as at 14 September 2020 the unaudited 
NAV per Ordinary share was 35.8p, an increase of 13.6p per Ordinary 
share from the unaudited NAV of 22.2p per Ordinary share (the unaudited 
NAV as at 30 June 2020 net of the dividend of 8p per Ordinary Share that 
was paid on 28 August 2020). This increase is a result of the profit 
generated on the sale of Omega and Scancell shares, and the increase in 
value of the remaining Scancell shares, net of the associated movement 
in the performance fee accrual. 
 
   The information above is deemed by the Company to constitute inside 
information as stipulated under the Market Abuse Regulations (EU No. 
596/2014). Upon the publication of this announcement via a Regulatory 
Information Service this inside information is now considered to be in 
the public domain. 
 
   For further information, please contact: 
 
   John Hustler, Seneca Growth Capital VCT Plc at 
https://www.globenewswire.com/Tracker?data=SFI1o_Z6m6HvfkCgstkxYVwc80FvM9twdxXs1EIdj32l7Q-iurfZl9vRwt3QtlNJoc5Wa3UqlpeFTVl7odZMdYnsxDim3uGHE-5IlmaYT4zod9a9Sqwlk-28D7hxLrJA 
john.hustler@btconnect.com 
 
   Richard Manley, Seneca Growth Capital VCT Plc at 
https://www.globenewswire.com/Tracker?data=lT6P9xAswoyxMo4HVcG8LD-0DN5D3O703YVdkJp8KGcqAtHVQCJSwEBJyj_qukXBKKgEQmvumXJgGI5zyPT9mDcKWad8MMVi6Ixa8ZcI_ctOPhF7XPhngy_BAtZeep4jy1S1d1N_yK-vyXfZ2sv2TQ== 
Richard.Manley@senecapartners.co.uk

(END) Dow Jones Newswires

September 16, 2020 02:00 ET (06:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Seneca Growth Capital Vct (LSE:SVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Seneca Growth Capital Vct Charts.
Seneca Growth Capital Vct (LSE:SVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Seneca Growth Capital Vct Charts.